Merrimack Pharmaceuticals Inc (MACK) 13.44 $MACK
Rhabdomyosarcoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 22, 3:50AM CDT
The report "Rhabdomyosarcoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Rhabdomyosarcoma. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/rhabdomyosar...eport.html.
MACK: 13.44 (+0.18), GSK: 46.57 (-0.67), CELGZ: 2.87 (+0.04)
First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients
PR Newswire - Tue Apr 21, 7:00AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced updated clinical data from a multi-arm Phase 1 study of MM-141, a bispecific antibody targeting IGF-1R and ErbB3. The data were presented in an oral session by Dr. Mansoor Saleh, MD at the 2015 American Association for Cancer Research Annual Meeting in Philadelphia, PA. The trial evaluated the safety and tolerability of MM-141 as a monotherapy and in combination with everolimus or with nab-paclitaxel and gemcitabine in patients with advanced solid tumors.
MACK: 13.44 (+0.18)
Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer
PR Newswire - Mon Apr 20, 3:01PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced updated and final clinical results for the Phase 1 study of MM-302, a novel HER2-targeted liposomal doxorubicin, in HER2-positive metastatic breast cancer. The results were presented today by Patricia LoRusso, D.O., in a clinical trials plenary oral session at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA. Data described the safety and promising clinical activity of MM-302 in patients with advanced HER2-positive metastatic breast cancer.
MACK: 13.44 (+0.18)
Critical Alerts For GoDaddy, Disney, Arrowhead Research, Merrimack Pharmaceuticals and Organovo Released By InvestorsObserver
PR Newswire - Tue Apr 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GDDY, DIS, ARWR, MACK and ONVO.
MACK: 13.44 (+0.18), ARWR: 6.87 (+0.13), ONVO: 5.14 (+0.67), DIS: 107.94 (+0.26), GDDY: 24.77 (-0.01)
First Week of May 15th Options Trading For Merrimack Pharmaceuticals (MACK)
DividendChannel.com - Fri Apr 10, 9:44AM CDT
Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the May 15th expiration.
MACK: 13.44 (+0.18)
Global & USA Cancer Immunotherapy Market Analysis 2015-2020
M2 - Fri Apr 10, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z6tkxf/global_and_usa) has announced the addition of the "GLOBAL & USA CANCER IMMUNOTHERAPY MARKET ANALYSIS TO 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors" report to their offering. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Scope - An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies. - Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines. - Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs. - Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market). - Insight into the various immunotherapeutics available for specific cancer types. - Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics. - Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs. - Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs. - Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe. - Summary table to identify the category of immunotherapy drug offered by the 76 companies. Companies Mentioned - 30 of the 75 Companies Featured - Ablynx NV - Activartis Biotech GmbH - Advaxis Inc. - Aduro BioTech Inc. - Agenus Inc. - AlphaVax Inc. - Amgen Inc. - Antigen Express Inc. - Argos Therapeutics Inc. - Bavarian Nordic A/S - Bellicum Pharmaceuticals Inc. - Biogen Idec Inc.x - Biovest International Inc. - Genmab AS - GlaxoSmithKline - Gliknik Inc. - GlobeImmune Inc. - Heat Biologics Inc. - Immatics Biotechnologies GmbH - ImmunoCellular Therapeutics Ltd. - Merrimack Pharmaceuticals Inc. - Morphotek Inc. - NewLink Genetics Corp. - Northwest Biotherapeutics Inc. - NovaRx Corp. - OncoPep Inc. - Oncothyreon Inc. - OSE Pharma SA - Viventia Biotechnologies Inc. - Wilex AG For more information visit http://www.researchandmarkets.com/research/z6...al_and_usa
HTBX: 7.71 (-0.64), BIIB: 423.57 (+1.46), NWBO: 8.36 (-0.39), ADXS: 22.18 (+0.10), ADRO: 38.17 (-0.50), AMGN: 169.10 (+0.64), GSK: 46.57 (-0.67), ONTY: 1.80 (+0.03), IMUC: 0.53 (+0.02), MACK: 13.44 (+0.18), GBIM: 8.46 (+0.46), ARGS: 8.48 (-0.11), BLCM: 28.55 (+2.59), NLNK: 53.12 (-0.07)
Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors: Featuring 174 Companies
M2 - Thu Apr 09, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lkr3c/competitor) has announced the addition of the "Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors" report to their offering. This Competitive Intelligence Report about Therapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of April 2015. Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 82.2 bln ( 8.6% vs previous year) in the year 2014. The report lists specifically for each target the branded products with their 2014 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development. The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets: - VEGF - TNF - Her2 - CD20 - EGF-R - B7.1/B7.2 (CD80/CD86) - IL-6R - Alpha4/beta1/7 integrin - IgE - RSV - RANKL - Complement C5 - IL-12/IL-23 - CD52 Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage and additional comments with a hyperlink leading to the source of information Key Topics Covered: 1) 2014 Sales of Therapeutic Antibodies 2) VEGF Antibodies 3) TNF Antibodies 4) Her2 Antibodies 5) CD20 Antibodies 6) EGF-R Antibodies 7) RANKL Antibodies
Complement C5 Antibodies 9) Interleukin-12/-23 Antibodies 10) Alpha4/Beta1/7 Antibodies 11) IgE Antibodies 12) CD80/86 (B7-1/B7-2) Antibodies 13) Interleukin-6 Receptor (IL-6R) Antibodies 14) Respiratory Syncytial Virus (RSV) Antibodies 15) CD52 Antibodies Companies Mentioned: 30 of the 174 Companies Featured - 3SBio - AbbVie - Ablynx - Actavis - ActoGenix - ADC Therapeutics - AET Biotech - Celgene - Celltrion - Ceres Oncology - CIMAB - Clearside Biomedical - Eisai - Eli Lilly - Emergent BioSolutions - Epirus Biopharmaceuticals - Harvest Moon Pharmaceuticals - Hospira - Humabs Biomed - Merck Serono - Merrimack Pharmaceuticals - Mersana Therapeutics - Merus - Reliance Life Sciences - Roche - R-Pharm - RuiYi - Samsung Bioepis (JV of Samsung and Biogen Idec) - Sanofi - Shanghai BioMabs Pharmaceutical For more information visit http://www.researchandmarkets.com/research/4lkr3c/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MACK: 13.44 (+0.18), BIIB: 423.57 (+1.46), EBS: 29.84 (-0.13), MRK: 57.69 (+0.03), LLY: 72.30 (+0.09), CELGZ: 2.87 (+0.04)
Gastroesophageal (GE) Junction Carcinomas Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 6:30AM CDT
The report "Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas. The gastroesophageal junction lies at the top of the stomach in the upper abdomen. Conditions that afflict the gastroesophageal junction include hiatal hernia. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/gastroesopha...eport.html .
MACK: 13.44 (+0.18), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), BMY: 66.60 (-0.21), EXEL: 3.12 (+0.05)
Insider Trading Alert - MACK, NUAN And NFX Traded By Insiders
at The Street - Fri Mar 27, 10:30AM CDT
Stocks with insider trader activity include MACK, NUAN and NFX
MACK: 13.44 (+0.18), NFX: 37.77 (+0.79), NUAN: 14.26 (+0.10)
Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting
PR Newswire - Thu Mar 26, 7:00AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present preclinical and clinical data showcasing its deep oncology pipeline at the 2015 American Association for Cancer Research (AACR) Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia. The presentations describe recent data from Merrimack's proprietary antibody engineering and nanoliposomal technology platforms, as well as oral presentations on Phase 1 clinical trials of MM-302 and MM-141.
MACK: 13.44 (+0.18)
Biotech Equities Technical Coverage - ZIOPHARM Oncology, Arrowhead Research, Merrimack Pharma, Vertex Pharma, and Advaxis
PR Newswire - Wed Mar 25, 8:41AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MACK: 13.44 (+0.18), ADXS: 22.18 (+0.10), VRTX: 132.85 (+0.65), ZIOP: 10.88 (+0.03), ARWR: 6.87 (+0.13)
Weak On High Volume: Merrimack Pharmaceuticals (MACK)
at The Street - Mon Mar 23, 9:02AM CDT
Trade-Ideas LLC identified Merrimack Pharmaceuticals (MACK) as a weak on high relative volume candidate
MACK: 13.44 (+0.18)
Insider Trading Alert - AEL, BWA And MACK Traded By Insiders
at The Street - Mon Mar 16, 10:15AM CDT
Stocks with insider trader activity include AEL, BWA and MACK
MACK: 13.44 (+0.18), BWA: 60.99 (+0.04), AEL: 29.67 (+0.09)
Onxeo: An Upcoming Mid-Sized Pharma With Ambitions
Logribel Biostocks - at Seeking Alpha - Thu Mar 12, 1:58PM CDT
MACK: 13.44 (+0.18), RNN: 0.73 (-0.03), PTBI: 3.37 (+0.20), DARA: 0.75 (+0.02), BIND: 7.01 (-0.30)
Esophageal Cancer Therapeutics Pipeline Review 2015 - 40 Companies & 57 Drug Profiles
M2 - Wed Mar 11, 7:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2mqnm8/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Advaxis, Inc. - Amgen Inc. - ArQule, Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellectar Biosciences, Inc. - Cerulean Pharma, Inc. - Daiichi Sankyo Company, Limited - Genmab A/S - GlaxoSmithKline plc - Glycotope GmbH - Hutchison MediPharma Limited - ImmunoFrontier, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Karyopharm Therapeutics, Inc. - Mebiopharm Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Omnitura Therapeutics Inc. - Oncolys BioPharma Inc. - Ono Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2m...eal_cancer
CLRB: 3.20 (unch), IMMU: 4.14 (-0.04), ADXS: 22.18 (+0.10), CERU: 5.99 (-0.20), IMGN: 9.96 (+0.01), ARQL: 2.11 (-0.03), AMGN: 169.10 (+0.64), GSK: 46.57 (-0.67), BMY: 66.60 (-0.21), OMER: 24.41 (-0.15), MACK: 13.44 (+0.18), BLCM: 28.55 (+2.59), AZN: 73.35 (+0.65), AVEO: 2.04 (+0.12), NVS: 103.45 (-0.62), KPTI: 32.24 (-0.60), CELGZ: 2.87 (+0.04)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 4:38PM CDT
MACK: 13.44 (+0.18), MHR: 2.34 (-0.07), WB: 16.09 (+1.56), TXMD: 7.17 (+0.01), ANTH: 4.79 (+0.10), HABT: 33.00 (+0.55), NAV: 29.89 (+0.41), PES: 6.26 (-0.24), MERC: 14.10 (-0.19), GCA: 7.74 (+0.17)
Advanced Cell Diagnostics' RNAscope Technology Supports Biomarker-Selected Phase 2 Clinical Trial of Merrimack Pharmaceuticals' MM-121
PR Newswire - Mon Mar 09, 7:00AM CDT
Advanced Cell Diagnostics, Inc. (ACD) announced today that Merrimack Pharmaceuticals, Inc. is using ACD's RNAscope technology to select patients for its Phase 2 clinical trial of its product candidate MM-121. Merrimack will utilize RNAscope to identify patients with heregulin positive, locally advanced or metastatic non-small cell lung cancer, making this Merrimack's first MM-121 trial to include only patients with a high heregulin biomarker profile. In previous MM-121 Phase 2 clinical trials, heregulin-positive patients, determined by RNAscope, have demonstrated significant therapeutic benefits when treated with a combination of MM-121 and standard therapies.
MACK: 13.44 (+0.18)
Strong On High Relative Volume: Merrimack Pharmaceuticals (MACK)
at The Street - Thu Mar 05, 9:01AM CST
Trade-Ideas LLC identified Merrimack Pharmaceuticals (MACK) as a strong on high relative volume candidate
MACK: 13.44 (+0.18)
Bank Of America Is A Concern - Cramer's Lightning Round (3/2/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Mar 03, 5:54AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, March 2. Bullish Call: Merrimack Pharma (NASDAQ: MACK ): "We like them. That was one of our big pharma picks. We still continue to like it and I...
MACK: 13.44 (+0.18), MU: 29.50 (+0.95), HD: 112.99 (-0.18), AMX: 21.85 (-0.08), QTWO: 20.06 (+0.04), LOW: 73.07 (-0.17), WFC: 54.67 (+0.39), BAC: 15.74 (+0.24), MSFT: 42.99 (+0.36), MFRM: 63.45 (-0.24), HPQ: 33.51 (+0.30), VZ: 49.57 (+0.40)
'Mad Money' Lightning Round: I'm a Wells Fargo Guy, Unlike Buffett
at The Street - Tue Mar 03, 5:00AM CST
Cramer prefers Verizon over America Movil and Merrimack Pharmaceuticals is a good stock to own.
MACK: 13.44 (+0.18), MU: 29.50 (+0.95), HD: 112.99 (-0.18), AMX: 21.85 (-0.08), B: 40.81 (+0.32), LEG: 44.32 (unch), WFC: 54.67 (+0.39), LOW: 73.07 (-0.17), VZ: 49.57 (+0.40), MFRM: 63.45 (-0.24)
Rhabdomyosarcoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 22, 3:50AM CDT
The report "Rhabdomyosarcoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Rhabdomyosarcoma. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/rhabdomyosar...eport.html.
MACK: 13.44 (+0.18), GSK: 46.57 (-0.67), CELGZ: 2.87 (+0.04)
First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients
PR Newswire - Tue Apr 21, 7:00AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced updated clinical data from a multi-arm Phase 1 study of MM-141, a bispecific antibody targeting IGF-1R and ErbB3. The data were presented in an oral session by Dr. Mansoor Saleh, MD at the 2015 American Association for Cancer Research Annual Meeting in Philadelphia, PA. The trial evaluated the safety and tolerability of MM-141 as a monotherapy and in combination with everolimus or with nab-paclitaxel and gemcitabine in patients with advanced solid tumors.
MACK: 13.44 (+0.18)
Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer
PR Newswire - Mon Apr 20, 3:01PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced updated and final clinical results for the Phase 1 study of MM-302, a novel HER2-targeted liposomal doxorubicin, in HER2-positive metastatic breast cancer. The results were presented today by Patricia LoRusso, D.O., in a clinical trials plenary oral session at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA. Data described the safety and promising clinical activity of MM-302 in patients with advanced HER2-positive metastatic breast cancer.
MACK: 13.44 (+0.18)
Critical Alerts For GoDaddy, Disney, Arrowhead Research, Merrimack Pharmaceuticals and Organovo Released By InvestorsObserver
PR Newswire - Tue Apr 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GDDY, DIS, ARWR, MACK and ONVO.
MACK: 13.44 (+0.18), ARWR: 6.87 (+0.13), ONVO: 5.14 (+0.67), DIS: 107.94 (+0.26), GDDY: 24.77 (-0.01)
First Week of May 15th Options Trading For Merrimack Pharmaceuticals (MACK)
DividendChannel.com - Fri Apr 10, 9:44AM CDT
Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the May 15th expiration.
MACK: 13.44 (+0.18)
Global & USA Cancer Immunotherapy Market Analysis 2015-2020
M2 - Fri Apr 10, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z6tkxf/global_and_usa) has announced the addition of the "GLOBAL & USA CANCER IMMUNOTHERAPY MARKET ANALYSIS TO 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors" report to their offering. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Scope - An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies. - Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines. - Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs. - Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market). - Insight into the various immunotherapeutics available for specific cancer types. - Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics. - Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs. - Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs. - Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe. - Summary table to identify the category of immunotherapy drug offered by the 76 companies. Companies Mentioned - 30 of the 75 Companies Featured - Ablynx NV - Activartis Biotech GmbH - Advaxis Inc. - Aduro BioTech Inc. - Agenus Inc. - AlphaVax Inc. - Amgen Inc. - Antigen Express Inc. - Argos Therapeutics Inc. - Bavarian Nordic A/S - Bellicum Pharmaceuticals Inc. - Biogen Idec Inc.x - Biovest International Inc. - Genmab AS - GlaxoSmithKline - Gliknik Inc. - GlobeImmune Inc. - Heat Biologics Inc. - Immatics Biotechnologies GmbH - ImmunoCellular Therapeutics Ltd. - Merrimack Pharmaceuticals Inc. - Morphotek Inc. - NewLink Genetics Corp. - Northwest Biotherapeutics Inc. - NovaRx Corp. - OncoPep Inc. - Oncothyreon Inc. - OSE Pharma SA - Viventia Biotechnologies Inc. - Wilex AG For more information visit http://www.researchandmarkets.com/research/z6...al_and_usa
HTBX: 7.71 (-0.64), BIIB: 423.57 (+1.46), NWBO: 8.36 (-0.39), ADXS: 22.18 (+0.10), ADRO: 38.17 (-0.50), AMGN: 169.10 (+0.64), GSK: 46.57 (-0.67), ONTY: 1.80 (+0.03), IMUC: 0.53 (+0.02), MACK: 13.44 (+0.18), GBIM: 8.46 (+0.46), ARGS: 8.48 (-0.11), BLCM: 28.55 (+2.59), NLNK: 53.12 (-0.07)
Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors: Featuring 174 Companies
M2 - Thu Apr 09, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lkr3c/competitor) has announced the addition of the "Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors" report to their offering. This Competitive Intelligence Report about Therapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of April 2015. Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 82.2 bln ( 8.6% vs previous year) in the year 2014. The report lists specifically for each target the branded products with their 2014 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development. The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets: - VEGF - TNF - Her2 - CD20 - EGF-R - B7.1/B7.2 (CD80/CD86) - IL-6R - Alpha4/beta1/7 integrin - IgE - RSV - RANKL - Complement C5 - IL-12/IL-23 - CD52 Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage and additional comments with a hyperlink leading to the source of information Key Topics Covered: 1) 2014 Sales of Therapeutic Antibodies 2) VEGF Antibodies 3) TNF Antibodies 4) Her2 Antibodies 5) CD20 Antibodies 6) EGF-R Antibodies 7) RANKL Antibodies
Complement C5 Antibodies 9) Interleukin-12/-23 Antibodies 10) Alpha4/Beta1/7 Antibodies 11) IgE Antibodies 12) CD80/86 (B7-1/B7-2) Antibodies 13) Interleukin-6 Receptor (IL-6R) Antibodies 14) Respiratory Syncytial Virus (RSV) Antibodies 15) CD52 Antibodies Companies Mentioned: 30 of the 174 Companies Featured - 3SBio - AbbVie - Ablynx - Actavis - ActoGenix - ADC Therapeutics - AET Biotech - Celgene - Celltrion - Ceres Oncology - CIMAB - Clearside Biomedical - Eisai - Eli Lilly - Emergent BioSolutions - Epirus Biopharmaceuticals - Harvest Moon Pharmaceuticals - Hospira - Humabs Biomed - Merck Serono - Merrimack Pharmaceuticals - Mersana Therapeutics - Merus - Reliance Life Sciences - Roche - R-Pharm - RuiYi - Samsung Bioepis (JV of Samsung and Biogen Idec) - Sanofi - Shanghai BioMabs Pharmaceutical For more information visit http://www.researchandmarkets.com/research/4lkr3c/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. MACK: 13.44 (+0.18), BIIB: 423.57 (+1.46), EBS: 29.84 (-0.13), MRK: 57.69 (+0.03), LLY: 72.30 (+0.09), CELGZ: 2.87 (+0.04)
Gastroesophageal (GE) Junction Carcinomas Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 6:30AM CDT
The report "Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas. The gastroesophageal junction lies at the top of the stomach in the upper abdomen. Conditions that afflict the gastroesophageal junction include hiatal hernia. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/gastroesopha...eport.html .
MACK: 13.44 (+0.18), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), BMY: 66.60 (-0.21), EXEL: 3.12 (+0.05)
Insider Trading Alert - MACK, NUAN And NFX Traded By Insiders
at The Street - Fri Mar 27, 10:30AM CDT
Stocks with insider trader activity include MACK, NUAN and NFX
MACK: 13.44 (+0.18), NFX: 37.77 (+0.79), NUAN: 14.26 (+0.10)
Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting
PR Newswire - Thu Mar 26, 7:00AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present preclinical and clinical data showcasing its deep oncology pipeline at the 2015 American Association for Cancer Research (AACR) Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia. The presentations describe recent data from Merrimack's proprietary antibody engineering and nanoliposomal technology platforms, as well as oral presentations on Phase 1 clinical trials of MM-302 and MM-141.
MACK: 13.44 (+0.18)
Biotech Equities Technical Coverage - ZIOPHARM Oncology, Arrowhead Research, Merrimack Pharma, Vertex Pharma, and Advaxis
PR Newswire - Wed Mar 25, 8:41AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MACK: 13.44 (+0.18), ADXS: 22.18 (+0.10), VRTX: 132.85 (+0.65), ZIOP: 10.88 (+0.03), ARWR: 6.87 (+0.13)
Weak On High Volume: Merrimack Pharmaceuticals (MACK)
at The Street - Mon Mar 23, 9:02AM CDT
Trade-Ideas LLC identified Merrimack Pharmaceuticals (MACK) as a weak on high relative volume candidate
MACK: 13.44 (+0.18)
Insider Trading Alert - AEL, BWA And MACK Traded By Insiders
at The Street - Mon Mar 16, 10:15AM CDT
Stocks with insider trader activity include AEL, BWA and MACK
MACK: 13.44 (+0.18), BWA: 60.99 (+0.04), AEL: 29.67 (+0.09)
Onxeo: An Upcoming Mid-Sized Pharma With Ambitions
Logribel Biostocks - at Seeking Alpha - Thu Mar 12, 1:58PM CDT
MACK: 13.44 (+0.18), RNN: 0.73 (-0.03), PTBI: 3.37 (+0.20), DARA: 0.75 (+0.02), BIND: 7.01 (-0.30)
Esophageal Cancer Therapeutics Pipeline Review 2015 - 40 Companies & 57 Drug Profiles
M2 - Wed Mar 11, 7:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2mqnm8/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Advaxis, Inc. - Amgen Inc. - ArQule, Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellectar Biosciences, Inc. - Cerulean Pharma, Inc. - Daiichi Sankyo Company, Limited - Genmab A/S - GlaxoSmithKline plc - Glycotope GmbH - Hutchison MediPharma Limited - ImmunoFrontier, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Karyopharm Therapeutics, Inc. - Mebiopharm Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Omnitura Therapeutics Inc. - Oncolys BioPharma Inc. - Ono Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2m...eal_cancer
CLRB: 3.20 (unch), IMMU: 4.14 (-0.04), ADXS: 22.18 (+0.10), CERU: 5.99 (-0.20), IMGN: 9.96 (+0.01), ARQL: 2.11 (-0.03), AMGN: 169.10 (+0.64), GSK: 46.57 (-0.67), BMY: 66.60 (-0.21), OMER: 24.41 (-0.15), MACK: 13.44 (+0.18), BLCM: 28.55 (+2.59), AZN: 73.35 (+0.65), AVEO: 2.04 (+0.12), NVS: 103.45 (-0.62), KPTI: 32.24 (-0.60), CELGZ: 2.87 (+0.04)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 4:38PM CDT
MACK: 13.44 (+0.18), MHR: 2.34 (-0.07), WB: 16.09 (+1.56), TXMD: 7.17 (+0.01), ANTH: 4.79 (+0.10), HABT: 33.00 (+0.55), NAV: 29.89 (+0.41), PES: 6.26 (-0.24), MERC: 14.10 (-0.19), GCA: 7.74 (+0.17)
Advanced Cell Diagnostics' RNAscope Technology Supports Biomarker-Selected Phase 2 Clinical Trial of Merrimack Pharmaceuticals' MM-121
PR Newswire - Mon Mar 09, 7:00AM CDT
Advanced Cell Diagnostics, Inc. (ACD) announced today that Merrimack Pharmaceuticals, Inc. is using ACD's RNAscope technology to select patients for its Phase 2 clinical trial of its product candidate MM-121. Merrimack will utilize RNAscope to identify patients with heregulin positive, locally advanced or metastatic non-small cell lung cancer, making this Merrimack's first MM-121 trial to include only patients with a high heregulin biomarker profile. In previous MM-121 Phase 2 clinical trials, heregulin-positive patients, determined by RNAscope, have demonstrated significant therapeutic benefits when treated with a combination of MM-121 and standard therapies.
MACK: 13.44 (+0.18)
Strong On High Relative Volume: Merrimack Pharmaceuticals (MACK)
at The Street - Thu Mar 05, 9:01AM CST
Trade-Ideas LLC identified Merrimack Pharmaceuticals (MACK) as a strong on high relative volume candidate
MACK: 13.44 (+0.18)
Bank Of America Is A Concern - Cramer's Lightning Round (3/2/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Mar 03, 5:54AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, March 2. Bullish Call: Merrimack Pharma (NASDAQ: MACK ): "We like them. That was one of our big pharma picks. We still continue to like it and I...
MACK: 13.44 (+0.18), MU: 29.50 (+0.95), HD: 112.99 (-0.18), AMX: 21.85 (-0.08), QTWO: 20.06 (+0.04), LOW: 73.07 (-0.17), WFC: 54.67 (+0.39), BAC: 15.74 (+0.24), MSFT: 42.99 (+0.36), MFRM: 63.45 (-0.24), HPQ: 33.51 (+0.30), VZ: 49.57 (+0.40)
'Mad Money' Lightning Round: I'm a Wells Fargo Guy, Unlike Buffett
at The Street - Tue Mar 03, 5:00AM CST
Cramer prefers Verizon over America Movil and Merrimack Pharmaceuticals is a good stock to own.
MACK: 13.44 (+0.18), MU: 29.50 (+0.95), HD: 112.99 (-0.18), AMX: 21.85 (-0.08), B: 40.81 (+0.32), LEG: 44.32 (unch), WFC: 54.67 (+0.39), LOW: 73.07 (-0.17), VZ: 49.57 (+0.40), MFRM: 63.45 (-0.24)
